首页> 美国卫生研究院文献>BMJ Open >Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised open-label phase III trial

【2h】

Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised open-label phase III trial

机译：Pembrolizuab用于治疗中国铂抗性或转移性头部和颈鳞状细胞癌的成本效果：基于随机开放标签第三阶段试验的经济分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Pembrolizumab was recently demonstrated to have survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma (r/mHNSCC). However, the cost-effectiveness of pembrolizumab versus chemotherapy in China remains uncertain.

机译：最近彭布洛司可展示了复发性或转移头和颈部鳞状细胞癌（R / MHNSCC）的患者中生存效益。然而，中国彭洛洛洛妥昔单抗与化疗的成本效益仍然不确定。

著录项

期刊名称 BMJ Open
作者
Wenxiu Xin; Haiying Ding; Qilu Fang; Xiaowei Zheng; Yinghui Tong; Gaoqi Xu; Guonong Yang;
展开▼
作者单位

展开▼
年(卷),期 2020(10),12
年度 2020
页码 e038867
总页数 6
原文格式 PDF
正文语种
中图分类
关键词
clinical pharmacology; health economics; head neck tumours;

机译：临床药理学;卫生经济学;头部和颈部肿瘤;

相似文献

外文文献
中文文献
专利

1. CMAB009联合伊立替康或伊立替康单药二线治疗氟嘧啶和奥沙利铂治疗失败的KRAS野生型转移性结直肠癌患者的研究:一项前瞻性、开放、随机、Ⅲ期试验 [J] . 石远凯, 白丽, 张沂平, 癌症（英文版） . 2020,第007期
2. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial [J] . Machiels Jean-Pascal H., Haddad Robert I., Fayette Jerome, The lancet oncology . 2015,第5期

机译：阿法替尼vs甲氨蝶呤作为铂类疗法治疗后或复发的复发性或转移性头颈部鳞状细胞癌患者的二线治疗（LUX-Head＆Neck 1）：一项开放性，随机，3期试验
3. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial [J] . Seiwert Tanguy Y., Burtness Barbara, Mehra Ranee, The lancet oncology . 2016,第7期

机译：派姆单抗治疗头颈部复发或转移性鳞状细胞癌的安全性和临床活性（KEYNOTE-012）：一项开放性，多中心，1b期临床试验
4. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy [J] . Jean-Pascal H Machiels, Lisa F Licitra, Robert I Haddad, BMC Cancer . 2014,第1期

机译：LUX-Head＆Neck的原理和设计1：阿法替尼与甲氨蝶呤在铂类药物治疗后复发和/或转移性头颈部鳞状细胞癌患者中进行的一项随机，III期临床试验
5. Interstitial photodynamic therapy in combination with Cetuximab for recurrent head and neck squamous cell carcinoma [C] . Nestor Rigual, Ambujakshan Dildeep, Gal Shafirstein Conference on photonic therapeutics and diagnostics IX . 2013

机译：间质性光动力疗法联合西妥昔单抗治疗复发性头颈部鳞状细胞癌
6. Inflammatory mechanisms of chemokine receptor 7 expression in metastatic squamous cell carcinoma of the head and neck (SCCHN). [D] . Mburu, Yvonne K. 2011

机译：趋化因子受体7在头颈部转移性鳞状细胞癌（SCCHN）中表达的炎症机制。
7. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head Neck 3): an open-label randomised phase III trial [O] . Y Guo, M -J Ahn, A Chan, -1

机译：阿法替尼与甲氨蝶呤作为亚洲复发或转移性鳞状鳞癌的亚洲患者二线治疗在铂类疗法治疗之后或之后进行（LUX-Head＆Neck 3）：一项开放性随机III期试验
8. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial [O] . Wenxiu Xin, Haiying Ding, Qilu Fang, 2020

机译：Pembrolizuab用于治疗中国铂抗性或转移性头部和颈鳞状细胞癌的成本效果：基于随机开放标签，第三阶段试验的经济分析

Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised open-label phase III trial

摘要

著录项

相似文献

相关主题

期刊订阅